Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 62, Issue 2, 1999, Pages 135-141

  Nousiainen, Tapio ^a   Jantunen, E ^a   Vanninen, E ^a   Remes, J ^b   Vuolteenaho, O ^c   Hartikainen, J ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b SATAKUNTA CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Cardiotoxicity; Doxorubicin; Natriuretic peptides; Non Hodgkin's lymphoma; Radionuclide ventriculography

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; NATRIURETIC FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; TREATMENT OUTCOME;

EID: 0032909472     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01734.x     Document Type: Article

References (22)

1. VON HOFF DD, LAYARD MW, BASA P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
2. ALEXANDER J, DAINIAK N, BERGER HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278-283.
3. SCHWARTZ RG, MCKENZIE WB, ALEXANDER J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109-1118.
4. GANZ WI, SRIDHAR KS, GANZ SS, GONZALEZ R, CHAKKO S, SERAFINI A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996;53:461-470.
5. FRANCIS GS, BENEDICT C, JOHNSTONE DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-1729.
6. REMES J, TIKKANEN I, FYHRQUIST F, PYÖRÄLÄ K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991;65:249-255.
7. LERMAN A, GIBBONS RJ, RODEHEFFER RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-1109.
8. MUKOYAMA M, NAKAO K, HOSODA K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-1412.
9. NERI B, DE SCALZI M, DE LEONARDIS V, GEMELLI MT, GHEZZI P, PACINI P. Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity. Int J Clin Pharm Res 1991;11:75-81.
10. BAUCH M, ESTER A, KIMURA B, VICTORIA BE, KEDAR A, PHILLIPS MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992;69:1492-1497.
11. THE NON-HODGKIN'S LYMPHOMA PATHOLOGIC CLASSIFICATION PROJECT. National Cancer Institute sponsored study of classification of non-Hodgkins's lymphomas: summary and description of a Working Formulation for clinical usage. Cancer 1982;49:2112-2135.
12. THE INTERNATIONAL NON-HODGKIN'S LYMPHOMA PROGNOSTIC FACTORS PROJECT. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
13. WACKERS FJ, BERGER HJ, JOHNSTONE DE, et al. Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: validation of the technique and assessment of variability. Am J Cardiol 1979;43:1159-1166.
14. MUSTONEN P, HIPPELÄINEN M, VANNINEN E, REHNBERG S, TENHUNEN-ESKELINEN M, HARTIKAINEN J. Significance of coronary artery bypass grafting-associated conduction defects. Am J Cardiol 1998;81:558-563.
15. VUOLTEENAHO O, KOISTINEN P, MARTIKKALA V, TAKALA T, LEPPÄLUOTO J. Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. Am J Physiol 1992;263:R647-R652.
16. VUOLTEENAHO O, ARJAMAA O, LING N. Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun 1985;129:82-88.
17. LIPSHULTZ SE, SANDERS SP, GOORIN AM, KRISCHER JP, SALLAN SE, COLAN SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433-437.
18. McDONAGH TA, ROBB SD, MURDOCH DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
19. COWIE MR, STRUTHERS AD, WOOD DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-1351.
20. YAMASHITA J-I, OGAWA M, SHIRAKUSA T. Plasma endothelin-1 as a marker for doxorubicin cardiotoxicity. Int J Cancer 1995;62:542-547.
21. HUNT PJ, RICHARDS AM, NICHOLLS MG, YANDLE TG, DOUGHTY RN, ESPINER EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287-296.
22. SWAIN SM, WHALEY FS, GERBER MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-1332.